40
Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 [email protected] Midwest Biopharmaceutical Statistics Workshop (MBSW) - MAY 23 - 25, 2011

Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 [email protected] Midwest Biopharmaceutical

Embed Size (px)

Citation preview

Page 1: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

Applying Change Point Detection in Vaccine Manufacturing

Hesham Fahmy, Ph.D.

Merck & Co., Inc.West Point, PA 19486

[email protected]

Midwest Biopharmaceutical Statistics Workshop (MBSW) - MAY 23 - 25, 2011

Page 2: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

2

Outline

Definitions Detection methods CUSUM and EWMA estimators

Case studies CUSUM and EWMA SSE

Conclusions

Page 3: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

3

Methods of Detection

Visual (Simple but Subjective) Raw data; run chart CUSUM chart EWMA chart

Analytical (Complicated but Objective) Change-Point estimators; i.e. CUSUM,

EWMA Mathematical Modeling; i.e. MLE, SSE

Page 4: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

4

Types of Variation

Common Causes – natural (random) variations that are part of a stable processMachine vibrationMachine vibrationTemperature, humidity, electrical current fluctuationsTemperature, humidity, electrical current fluctuationsSlight variation in raw materialsSlight variation in raw materials

Special Causes – unnatural (non-random) variations that are not part of a stable processBatch of defective raw materialBatch of defective raw materialFaulty set-upFaulty set-upHuman errorHuman errorIncorrect recipeIncorrect recipe

Page 5: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

5

Cumulative Sum Control Chart CUSUM: cumulative sum of deviations from

average

A bit more difficult to set up More difficult to understand Very effective when subgroup size n=1 Very good for detecting small shifts Change-point detection capability Less sensitive to autocorrelation

10,0max ttt CKyC

0 wabove/belo deviations daccumulate tC

Page 6: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

6

Exponentially Weighted Moving Average

EWMA: weighted average of all observations

A bit more difficult to set upVery good for detecting small shiftsChange point detection capabilityLess sensitive to autocorrelation

“EWMA gives more weight to more recent observations and less weight to old observations.”

-1t

0j

-1 01 EyE tjt

jt

CUSUM Shewhart0 1

Page 7: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

7

Process Shifts

Step Linear Nonlinear

Others

Page 8: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

8

Process Model

in-control state

out-of-control state

t

Change point, "Unknown"

Page 9: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

9

Change-Point Estimation Procedures

CUSUM Change-Point Estimation Procedure (Page 1954)

HCTtiHCCt TitCUSUM ,1,....1 0 ,0:̂

EWMA Change-Point Estimation Procedure (Nishina 1992)

TTiitEWMA UCLETtiUCLEEt ,1,....,1 ,:ˆ 00

0 wabove/belo deviations daccumulate tC

Page 10: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

10

Example:

HCTtiHCCt TitCUSUM ,1,....1 0 ,0:̂

y

8

9

10

11

12

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

t

Process Data

10,0max ttt CKyC C

+

0

1

2

3

4

5

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

t

Upper CUSUM Chart

5H

5.0K

Most Recent Reintialization at t =22

Actual Change-Point= 20

Page 11: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

11

Example: y

8

9

10

11

12

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

t

Process Data

TTiitEWMA UCLETtiUCLEEt ,1,....,1 ,:ˆ 00

11 ttt EyE 2.0

1000 E

E

9.5

10.0

10.5

11.0

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

t

EWMA Chart

UCL=11

LCL=9

tE at t =19Most Recent time

Actual Change-Point= 20

Page 12: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

12

Real Example

29.0

30.0

31.0

32.0

33.0

Run

Cha

rt o

f Pro

dx

25 50 75 100

125

150

175

200

225

250

275

300

325

350

375

400

425

450

Sample

Run Chart of Prodx

Page 13: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

13

CUSUM vs. EWMA

-10

0

10

20

30

40

50

60

70

80

90

100

110

120

130

140

Cum

ulat

ive

Sum

of P

rodx

25 50 75 100

125

150

175

200

225

250

275

300

325

350

375

400

425

450

Sample

CUSUM of Prodx

31.06

31.07

31.08

31.09

31.10

31.11

31.12

31.13

31.14

EW

MA

of P

rodx

25 75 125

175

225

275

325

375

425

Sample

Avg=31.0870

EWMA of Prodx, Lamda=0.001

Page 14: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

14

5.0

2.0

29.5

30.0

30.5

31.0

31.5

32.0

32.5

EW

MA

of P

rodx

25 50 75 100

125

150

175

200

225

250

275

300

325

350

375

400

425

450

Sample

Avg=31.087

EWMA of Prodx, Lamda= 0.2

29.5

30.0

30.5

31.0

31.5

32.0

32.5

EW

MA

of P

rodx

25 50 75 100

125

150

175

200

225

250

275

300

325

350

375

400

425

450

Sample

Avg=31.087

EWMA of Prodx, Lamda= 0.5

Page 15: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

15

Simulated Case Studies

To test different methods' (control charts/analytical) capability for identifying change-points Case # 1: small shifts/drifts Case # 2: mirror image of case # 1 Case # 3: large shifts/drifts

Page 16: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

16

Case #1

-6

-5

-4

-3

-2

-1

0

1

2

3

4

Run C

hart

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Run Chart of Y

-6

-5

-4

-3

-2

-1

0

1

2

3

4

Run C

hart

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Run Chart of Y

Page 17: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

17

Case # 1

-7

-6

-5

-4

-3

-2

-1

0

1

2

3

4

Y

1 2 3 4 5 6

0 25 50 75 100 125 150 175 200 225 250

Obs

Individual Measurement of Y

1 & 6: In-control process; N(0,1)

2 : -ve linear trend; 0.1 sigma

3 : Step shift; N(-3,1)

4 : Step shift; N(-1.5,1)

5 : +ve linear trend; 0.1 sigma

Page 18: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

18

-100

-75

-50

-25

0

25

50

75

100

Cum

ula

tive S

um

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y (Alpha=0.0027)

CUSUM (V-Mask)

-6

-5

-4

-3

-2

-1

0

1

2

3

4

Run

Cha

rt of

Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Run Chart of Y

Detection Criterion: Slope Change

-3

-2

-1

0

1

2

3

Run

Cha

rt o

f Y

40 42 44 46 48 50 52 54 56 58 60

Sample

Samples 40 to 60

Diagnostic Sequence Plot

Page 19: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

19

-100

-75

-50

-25

0

25

50

75

100

Cum

ulat

ive

Sum

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y (Alpha=0.01)

CUSUM; 01.0

0027.0

Exact Profile-100

-75

-50

-25

0

25

50

75

100

Cum

ula

tive S

um

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y (Alpha=0.0027)

Page 20: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

20

CUSUM – Target Adjusted

-300

-200

-100

0C

umul

ativ

e S

um o

f Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y - Target= 0

-150

-100

-50

0

50

Cum

ulat

ive

Sum

of Y

0 25 50 75 100 125 150

Sample

CUSUM of Y - Target= 0

-300

-250

-200

-150

-100

Cum

ula

tive S

um

of Y

50 75 100 125 150 175 200

Sample

CUSUM of Y - Target= 0

Page 21: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

21

EWMA;

-5

-4

-3

-2

-1

0

1

2

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Avg=-1.11

EWMA of Y (Lamda=0.5)

5.0

-3

-2

-1

0

1

2

3

Run

Cha

rt o

f Y

40 42 44 46 48 50 52 54 56 58 60

Sample

Samples 40 to 60

Detection Criterion: Slope Change

Page 22: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

22

EWMA;

-1.20

-1.18

-1.16

-1.14

-1.12

-1.10

-1.08

-1.06

-1.04

-1.02

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Avg=-1.1080

EWMA of Y (Lamda=0.001)

001.0

-100

-75

-50

-25

0

25

50

75

100

Cum

ulat

ive

Sum

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y (Alpha=0.01)

CUSUM

Same Profile

Page 23: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

23

Case # 2 “Mirror Image”

-4

-3

-2

-1

0

1

2

3

4

5

6

7

Y

1 2 3 4 5 6

0 25 50 75 100 125 150 175 200 225 250

Sample

Individual Measurement of Y

1 & 6: In-control process; N(0,1)

2 : +ve linear trend; 0.1 sigma

3 : Step shift; N(3,1)

4 : Step shift; N(1.5,1)

5 : -ve linear trend; 0.1 sigma

Page 24: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

24

0

100

Cum

ulat

ive

Sum

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y

CUSUM Chart

-100

-75

-50

-25

0

25

50

75

100

Cum

ulat

ive

Sum

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y (Alpha=0.01)

Mirror Image

Case # 2

Case # 1

Page 25: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

25

0

50

100

150

200

250

300

350

Cum

ulat

ive

Sum

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y - Target= 0

CUSUM – Target Adjusted

Page 26: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

26

0.5

0.6

0.7

0.8

0.9

1.0

1.1

1.2

1.3

1.4

1.5

1.6

1.7

1.8

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Avg=0.992

EWMA of Y-Lamda=0.01

EWMA Chart; 01.0

Page 27: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

27

EWMA Chart; 2.0

-1

0

1

2

3

4

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Avg=0.99

EWMA of Y - Lamda=0.2

-1

0

1

2

3

4

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

µ0=0.00

EWMA of Y - Target= 0, Lamda= 0.2

Page 28: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

28

EWMA Chart;

-2

-1

0

1

2

3

4

5

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Avg=0.99

EWMA of Y-Lamda=0.5

5.0

Page 29: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

29

Case # 3

-5

-3

-1

1

3

5

7

9

11

13

15

17

Y

1 2 3 4 5 6

0 25 50 75 100 125 150 175 200 225 250

Sample

Individual Measurement of Y

1 & 6: In-control process; N(0,1)

2 : +ve linear trend; 0.5 sigma

3 : Step shift; N(12.5,1)

4 : Step shift; N(9.5,1)

5 : -ve linear trend; 0.38 sigma

Page 30: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

30

CUSUM

-300

-200

-100

0

100

200

300

400

Cum

ulat

ive

Sum

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y

Page 31: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

31

CUSUM – Target Adjusted

0

1000

Cum

ulat

ive

Sum

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

CUSUM of Y - Target=0

300

400

500

600

700

800

900

1000

1100

1200

1300

1400

Cum

ulat

ive

Sum

of Y

50 75 100 125 150 175 200

Sample

CUSUM of Y - Target=0

-500

-400

-300

-200

-100

0

100

200

300

400

500

600

Cum

ulat

ive

Sum

of Y

-25 0 25 50 75 100 125

Sample

CUSUM of Y - Target=0

Page 32: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

32

EWMA;

-2

0

2

4

6

8

10

12

14

16

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Avg=5.45

EWMA of Y, Lamda=0.5

5.0

Page 33: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

33

EWMA;

-2

0

2

4

6

8

10

12

14

16

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Avg=5.45

EWMA of Y, Lamda= 0.2

2.0

Page 34: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

34

EWMA;

-2

-1

0

1

2

3

4

5

67

8

9

10

11

12

13

14

15

EW

MA

of Y

0 25 50 75 100 125 150 175 200 225 250

Sample

Avg=5.45

EWMA of Y, Lamda=0.1

1.0

Page 35: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

35

Detection by SSE Pick a window of about 30 points

including the “investigated point” Fit a two-phase regression using all

possible change-points & calculate the SSE

Plot possible change-points vs. their SSEs

Page 36: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

36

-3

-2

-1

0

1

2

3

Y

20

21

22

23

24

25

26

27

28

29

30

31

32

SS

E

30 35 40 45 50 55 60 65 70

Obs

Left Scale: Y

Right Scale: SSE

35 to 65 Window

90% CI

-1

0

1

2

3

4

5

6

Y

28

30

32

34

36

38

40

42

44

SS

E

55 60 65 70 75 80 85 90 95

Obs

Left Scale: Y

Right Scale: SSE

60 to 90 Window

-1

0

1

2

3

4

5

Y

10

11

12

13

14

15

16

SS

E

105 110 115 120 125 130 135 140 145

Obs

Left Scale: Y

Right Scale: SSE

110 to 140 Window

-1

0

1

2

3

4

5

Y

105 110 115 120 125 130 135 140 145

Obs

Overlay Plot

Examples from Case # 2

Page 37: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

37

-5

-2.5

0

2.5

5

7.5

10

Y

10

20

30

40

50

60

70

SS

E

30 35 40 45 50 55 60 65 70

Obs

Left Scale: Y

Right Scale: SSE

35 to 65 Window

2.5

5

7.5

10

12.5

15

17.5

Y

20

30

40

50

60

70

80

90

100

SS

E

55 60 65 70 75 80 85 90 95

Obs

Left Scale: Y

Right Scale: SSE

60 to 90 Window

7

8

9

10

11

12

13

14

15

Y

10

15

20

25

SS

E

105 110 115 120 125 130 135 140 145

Obs

Left Scale: Y

Right Scale: SSE

110 to 140 Window

3

4

5

6

7

8

9

10

11

Y

15

20

25

30

35

40

45

50

55

60

SS

E

155 160 165 170 175 180 185 190 195

Obs

Left Scale: Y

Right Scale: SSE

160 to 190 Window

Examples from Case # 3

Page 38: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

38

Conclusions

Change-point problem is general and can be applied in many applications such as 4 parameter logistic regression and degradation curves.

Another application in manufacturing processes includes detection of the change-point for process variance.

It is preferred to combine both analytical and visual techniques; in addition to process expertise; to get accurate results.

Page 39: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

39

References

• Fahmy, H.M. and Elsayed, E.A., Drift Time Detection and Adjustment Procedures for Processes Subject to Linear Trend. Int. J. Prod. Research, 2006, 3257–3278.

• Montgomery, D. C., Int. to Stat. Quality Control, 1997, (John Wiley: NY).

• Nishina, K., A comparison of control charts from the viewpoint of change-point estimation. Qual. Reliabil. Eng. Int., 1992, 8, 537–541.

• Pignatiello, J.J. Jr. and Samuel, T.R., Estimation of the change point of a normal process mean in SPC applications. J. Qual. Tech., 2001, 33, 82–95.

• Samuel, T.R., Pignatiello Jr., J.J. and Calvin, J.A., Identifying the time of a step change with X control charts. Qual. Eng., 1998, 10, 521–527.

Page 40: Applying Change Point Detection in Vaccine Manufacturing Hesham Fahmy, Ph.D. Merck & Co., Inc. West Point, PA 19486 hesham_fahmy@merck.com Midwest Biopharmaceutical

40

Acknowledgements

Lori Pfahler Julia O’Neill Jim Lucas